Mariacristina Di Marco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4057408/publications.pdf

Version: 2024-02-01

48 papers 1,399

471509 17 h-index 36 g-index

53 all docs 53
docs citations

53 times ranked 2543 citing authors

#	Article	IF	CITATIONS
1	\hat{l}^2 2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell, 2018, 33, 75-90.e7.	16.8	287
2	Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. Journal of Gastrointestinal Surgery, 2015, 19, 1802-1812.	1.7	166
3	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncology Reports, 2010, 23, 1183-92.	2.6	116
4	Hypersensitivity reactions related to oxaliplatin (OHP). British Journal of Cancer, 2003, 89, 477-481.	6.4	113
5	Laparoscopic Versus Open Distal Pancreatectomy for Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal Surgery, 2015, 19, 770-781.	1.7	105
6	Neoadjuvant Therapy for Resectable Pancreatic Cancer. Annals of Surgery, 2021, 274, 713-720.	4.2	48
7	Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. Journal of Gastrointestinal Surgery, 2016, 20, 1595-1607.	1.7	38
8	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of Oncology, 2019, 30, 1959-1968.	1.2	37
9	Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Anticancer Research, 2020, 40, 465-472.	1.1	35
10	Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. International Journal of Surgery, 2017, 48, 189-194.	2.7	31
11	State of the art biological therapies in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 55.	2.0	30
12	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers, 2022, 14, 2429.	3.7	25
13	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. In Vivo, 2020, 34, 1701-1714.	1.3	23
14	Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Molecular Medicine Reports, 2015, 12, 7479-7484.	2.4	20
15	Specific Toxicity of Maintenance Olaparib <i>Versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. Anticancer Research, 2020, 40, 597-608.	1.1	20
16	Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. Cancer Letters, 2004, 208, 193-196.	7.2	17
17	Folate and prevention of colorectal cancer in ulcerative colitis. European Journal of Cancer Prevention, 2005, 14, 395-398.	1.3	17
18	Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses. Oncology Letters, 2016, 11, 3161-3166.	1.8	17

#	Article	IF	CITATIONS
19	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 2014, 46, 561-567.	0.9	16
20	Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter caseâ€control study (PAULAâ€1). Cancer Medicine, 2020, 9, 7879-7887.	2.8	16
21	Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results—a single-center experience. Updates in Surgery, 2020, 72, 1089-1096.	2.0	16
22	Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms. Pancreas, 2016, 45, 1243-1254.	1,1	12
23	Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study. Acta Biomedica, 2018, 89, 18-27.	0.3	12
24	Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma. Case Reports in Gastroenterology, 2012, 6, 530-537.	0.6	11
25	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer, 2019, 19, 569.	2.6	11
26	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genetics, 2020, 248-249, 57-62.	0.4	11
27	The use of comprehensive complication Index \hat{A}^{\otimes} in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center. Hpb, 2021, 23, 618-624.	0.3	10
28	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. Pancreatology, 2012, 12, 388-393.	1.1	9
29	Exocrine-Endocrine Pancreatic Cancer and α-Fetoprotein. Pancreas, 2008, 37, 223-225.	1.1	8
30	Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. International Journal of Oncology, 2018, 52, 1972-1980.	3.3	8
31	Pancreatic cyst surveillance imposes low psychological burden. Pancreatology, 2019, 19, 1061-1066.	1.1	8
32	Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression. Oncotarget, 2016, 7, 74797-74806.	1.8	7
33	Searching for novel multimodal treatments in oligometastatic pancreatic cancer. BMC Cancer, 2020, 20, 271.	2.6	5
34	Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. World Journal of Clinical Cases, 2020, 8, 1241-1250.	0.8	5
35	Comparing recist and Choi's criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer Journal of Clinical Oncology, 2013, 31, e15069-e15069.	1.6	4
36	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics, 2022, 12, 1058.	2.6	4

#	Article	IF	CITATIONS
37	Antiprotease Strategy in Pancreatic Cancer Treatment. Pancreas, 2014, 43, 53-63.	1.1	3
38	External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model. Updates in Surgery, 2021, 73, 429-438.	2.0	3
39	Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. BJR case Reports, 2018, 4, 20170086.	0.2	2
40	What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-Risk Stigmata?. Pancreas, 2019, 48, 1167-1174.	1.1	2
41	Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A "REAL LIFE―study Journal of Clinical Oncology, 2017, 35, 396-396.	1.6	2
42	Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World Journal of Gastrointestinal Oncology, 2020, 12, 1456-1463.	2.0	2
43	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncology Letters, 2011, 2, 195-200.	1.8	1
44	Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial. International Journal of Surgery, 2018, 51, 63-70.	2.7	1
45	The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study. Pain and Therapy, 2021, 10, 1171-1188.	3.2	1
46	New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. Journal of Clinical Oncology, 2012, 30, e14647-e14647.	1.6	0
47	Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques Journal of Clinical Oncology, 2014, 32, e15192-e15192.	1.6	O
48	Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing Journal of Clinical Oncology, 2015, 33, 4127-4127.	1.6	0